Document is current
Any future updates will be listed below
-
Authors
Amghar, Mariam https://orcid.org/0009-0001-0693-9241
Rausch, Tobias
Özgür, Hilal
Roscher, Mareike
Bauder-Wüst, Ulrike
Bruchertseifer, Frank
Morgenstern, Alfred
Beneš, Vladimír
Kratochwil, Clemens
Benešová-Schäfer, Martina
-
Funding
Funding for this research was provided by:
Deutsches Krebsforschungszentrum (DKFZ)
- License Information
-
More Information
Article History
Received: 2 October 2025
Accepted: 4 February 2026
First Online: 11 February 2026
Declarations
:
: This study received ethical approval (S-882/2020) from the Ethics Committee of the Medical Faculty at Heidelberg University. This project is a non-interventional, exploratory investigation focusing on therapy resistance in patients treated with [ 225 Ac]Ac-/[ 177 Lu]Lu-PSMA-617. The study complies with national regulations, the Declaration of Helsinki, and Good Clinical Practice (GCP) guidelines. Furthermore, in accordance with Paragraph 13(2b) of the German Pharmaceuticals Law, the therapy was administered as a salvage treatment for patients with mCRPC who had progressive disease and were either resistant to or ineligible for approved therapeutic options. Informed consent was obtained from all subjects involved in the study.
: Informed consent for publication of anonymized data was obtained from all participants included in the study.
: A patent application for PSMA-617 has been filed by the German Cancer Research Center (DKFZ) and the University Clinic Heidelberg (UKHD). Ulrike Bauder-Wüst, Clemens Kratochwil, and Martina Benešová-Schäfer are co-inventors of this patent.
